Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials

Journal of Psychiatric Research

Volumn 62, Issue , 2015, Pages 38-47

  Srisurapanont, Manit ^a   Suttajit, Sirijit ^a   Maneeton, Narong ^a   Maneeton, Benchalak ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Adverse effects; Aripiprazole; Clozapine; Drug augmentation; Metabolic syndrome; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; NEUROLEPTIC AGENT;

AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; CARDIOMETABOLIC RISK; CINAHL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SCOPUS; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WEB OF SCIENCE; WEIGHT CHANGE; DRUG POTENTIATION;

ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; CLOZAPINE; DRUG SYNERGISM; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84924289206     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.01.004     Document Type: Article

References (43)

1. American Diabetes A, American Psychiatric A, American Association of Clinical E, North American Association for the Study of O Consensus development conference on antipsychotic drugs and obesity and diabetes. JClin Psychiatry 2004, 65:267-272.
2. Barbui C., Accordini S., Nose M., Stroup S., Purgato M., Girlanda F., et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. JClin Psychopharmacol 2011, 31:266-273.
3. Caemmerer J., Correll C.U., Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012, 140:159-168.
4. Chang J.S., Ahn Y.M., Park H.J., Lee K.Y., Kim S.H., Kang U.G., et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. JClin Psychiatry 2008, 69:720-731.
5. Cipriani A., Accordini S., Nose M., Purgato M., Girlanda F., Tansella M., et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. JClin Psychopharmacol 2013, 33:533-537.
6. Conley R.R., Kelly D.L. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001, 50:898-911.
7. Croxtall J.D. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 2012, 26:155-183.
8. Davis J.M., Chen N., Glick I.D. Ameta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60:553-564.
9. Davis M.C., Fuller M.A., Strauss M.E., Konicki P.E., Jaskiw G.E. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatr Scand 2014, 130:30-39.
10. De Hert M., Cohen D., Bobes J., Cetkovich-Bakmas M., Leucht S., Ndetei D.M., et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011, 10:138-151.
11. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
12. Essali A., Al-Haj Haasan N., Li C., Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009, CD000059.
13. Fan X., Borba C.P., Copeland P., Hayden D., Freudenreich O., Goff D.C., et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013, 127:217-226.
14. Fleischhacker W.W., Heikkinen M.E., Olie J.P., Landsberg W., Dewaele P., McQuade R.D., et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010, 13:1115-1125.
15. Hatala R., Keitz S., Wyer P., Guyatt G., Evidence-Based Medicine Teaching Tips Working G Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 2005, 172:661-665.
16. Henderson D.C., Kunkel L., Nguyen D.D., Borba C.P., Daley T.B., Louie P.M., et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006, 113:142-147.
17. Higgins J., Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 2011, [updated March 2011], The Cochrane Collaboration.
18. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. Higgins J.P., Thompson S.G., Spiegelhalter D.J. Are-evaluation of random-effects meta-analysis. JR Stat Soc Ser A Stat Soc 2009, 172:137-159.
20. Kennedy J.L., Altar C.A., Taylor D.L., Degtiar I., Hornberger J.C. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014, 29:63-76.
21. Lancon C., Sapin C., Note I., Farisse J. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study. Int J Psychiatry Clin Pract 2006, 10:131-137.
22. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007, 116:317-333.
23. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEngl J Med 2005, 353:1209-1223.
24. Maayan L., Vakhrusheva J., Correll C.U. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010, 35:1520-1530.
25. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003, 61:123-136.
26. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163:600-610.
27. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., et al. Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003, 60:82-91.
28. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 2013, 39:306-318.
29. Mitsonis C.I., Dimopoulos N.P., Mitropoulos P.A., Kararizou E.G., Katsa A.N., Tsakiris F.E., et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:373-377.
30. Miyamoto S., Jarskog L.F., Fleischhacker W.W. New therapeutic approaches for treatment-resistant schizophrenia: a look to the future. JPsychiatr Res 2014, 58C:1-6.
31. Mizuno Y., Suzuki T., Nakagawa A., Yoshida K., Mimura M., Fleischhacker W.W., et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014, 40:1385-1403.
32. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. JClin Epidemiol 2009, 62:1006-1012.
33. Mossaheb N., Kaufmann R.M. Role of aripiprazole in treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 2012, 8:235-244.
34. Muscatello M.R., Bruno A., Pandolfo G., Micò U., Scimeca G., Di Nardo F., et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011, 127:93-99.
35. Osser D.N., Roudsari M.J., Manschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry 2013, 21:18-40.
36. Porcelli S., Balzarro B., Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012, 22:165-182.
37. Sommer I.E., Begemann M.J., Temmerman A., Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012, 38:1003-1011.
38. Stip E., Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 2010, 32(Suppl.1):S3-S20.
39. Swainston Harrison T., Perry C.M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004, 64:1715-1736.
40. Taylor D.M., Smith L., Gee S.H., Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 2012, 125:15-24.
41. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
42. Vayisoglu S., Anil Yagcioglu A.E., Yagcioglu S., Karahan S., Karci O., Gurel S.C., et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophr Res 2013, 143:207-214.
43. Ziegenbein M., Wittmann G., Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Investig 2006, 26:117-124.